Switching to ziprasidone in the clinical practice setting: an open-label study

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Medicine

Background:

• Schizophrenia treatment often requires medication adjustments due to partial response or tolerability issues.
• Ziprasidone is an atypical antipsychotic used for managing schizophrenia.
• Evaluating long-term outcomes of antipsychotic switching is crucial for optimizing patient care.

Purpose of the Study:

• To assess the long-term efficacy and tolerability of switching to ziprasidone monotherapy in schizophrenia patients.
• To evaluate the impact of ziprasidone on psychiatric symptoms, quality of life, functionality, and metabolic parameters.

Main Methods:

• An observational study followed 208 schizophrenia patients switched to ziprasidone monotherapy for 1 year.
• Efficacy was measured using the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) scales.
• Quality of life, functionality (GAF, WHO-DAS-II), and safety, including metabolic parameters, were also assessed.

Main Results:

• 42.5% of patients achieved a $\ge$30% reduction in BPRS total score.
• Significant improvements were observed in BPRS, CGI-S, CGI-I, GAF, and WHO-DAS-II scores (p < 0.001).
• Ziprasidone treatment led to weight decrease, reduced LDL cholesterol and triglycerides, and increased HDL cholesterol (p < 0.05).

Conclusions:

• Switching to ziprasidone is an effective strategy for patients with schizophrenia needing a change in antipsychotic medication.
• Ziprasidone demonstrates good tolerability and positive effects on metabolic parameters in a real-world clinical setting.
• The findings support ziprasidone as a viable option for improving outcomes in schizophrenia management.